Lilly's weight-loss drug cuts diabetes risk by 94% in three-year trial, company says
Eli Lilly’s weight loss drug cut the risk of developing Type 2 diabetes by 94% in prediabetic adults who were overweight or obese after three years of weekly injections, the company disclosed in a statement on Tuesday.
Eli Lilly’s weight loss drug cut the risk of developing Type 2 diabetes by 94% in prediabetic adults who were overweight or obese after three years of weekly injections, the company disclosed in a statement on Tuesday.
The Indianapolis, Indiana-based company said the data comes from the longest completed trial of the drug, adding that it reinforces the long-term benefits of tirzepatide — the chemical name of its Zepbound and Mounjaro treatments.
Shares of the company rose 1.6% to $936.25 in premarket trading. The stock has risen sharply in recent years, driven by the high demand for weight-loss treatments, establishing Lilly as the largest drugmaker by market capitalization.
Early results from the late-stage trial, “SURMOUNT-1,” were initially disclosed in 2022. The data at that time, which showed the drug helped significantly cut weight in obese patients, helped it snag U.S. regulatory approval.
In the trial involving 1,032 adults, patients who received weekly injections of the Lilly drug showed a 94% reduction in the risk of progression to Type 2 diabetes compared to placebo up to week 176.
Rating: 5